CoChat

The losartan renal protection study — rationale, study design and baseline characteristics of RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan)

Open access
Brenner, Barry M, Cooper, Mark E, de Zeeuw, Dick, Grunfeld, Jean-Pierre, Keane, William F, Kurokawa, Kiyoshi, McGill, Janet B, Mitch, William E, Parving, Hans Henrik, Remuzzi, Guiseppe, Ribeiro, Arthur B, Schluchter, Mark D, Snavely, Duane, Zhang, Zhongxin, Simpson, Roger, Ramjit, Denise, Shahinfar, Shahnaz, RENAAL Study Investigators · 2000 · Journal of the Renin-Angiotensin-Aldosterone System
Cited by 139

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

The RENAAL Study is a double-blind, placebo-controlled trial to evaluate the renal protective effects of losartan in Type 2 diabetic patients with nephropathy. The study has enrolled 1513 patients and is expected to continue for 3.5 years after the last patient has been entered. Eligible patients must have a urinary albumin:creatinine ratio of at least 300 mg/g and serum creatinine between 1.3 to 3.0 mg/dL. Eligible hypertensive or normotensive patients are randomised to receive either losartan or placebo, in addition to their existing antihypertensive therapy. Medications that block angiotensin production or action, are excluded. The primary endpoint is a composite of the time to first event of doubling of serum creatinine, end-stage renal disease, or death; secondary endpoints include cardiovascular events, progression of renal disease, and changes in proteinuria; tertiary endpoints include quality of life, healthcare resource utilisation, and amputations. Patients include Caucasians (48.6%), Blacks (15.2%), Asians (16.7%), and Hispanics (18.2%). Baseline urinary albumin:creatinine ratio and serum creatinine levels average 1867 mg/g and 1.9 mg/dL, respectively. Mean systolic and diastolic blood pressures are 153 and 82 mmHg, respectively. RENAAL will document whether blockade of the AII receptor with losartan produces clinical benefits in patients with Type 2 diabetes and nephropathy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3317/jraas.2000.062

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

Metadata

Authors
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Grunfeld, J.-P., Keane, W. F., Kurokawa, K., McGill, J. B., Mitch, W. E., Parving, H. H., Remuzzi, G., Ribeiro, A. B., Schluchter, M. D., Snavely, D., Zhang, Z., Simpson, R., Ramjit, D., Shahinfar, S., & RENAAL Study Investigators
Venue
Journal of the Renin-Angiotensin-Aldosterone System
Published
2000-12
Volume
1
Issue
4
Pages
328-335
ISSN
  • 1470-3203 (ISSN-L)
  • 1752-8976
OpenAlex
W1983269730
Cited by
139
References
5
FWCI
6.41
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.